High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature.
Anna-Maria GlobigA V HippP Otto-MoraMaximilian HeegL S MayerS EhlH SchwachaM BewtraV TomovRobert ThimmeP HasselblattBertram BengschPublished in: Nature communications (2022)
The immune-pathology in Crohn's disease is linked to dysregulated CD4+ T cell responses biased towards pathogenic TH17 cells. However, the role of CD8+ T cells able to produce IL-17 (Tc17 cells) remains unclear. Here we characterize the peripheral blood and intestinal tissue of Crohn's disease patients (n = 61) with flow and mass cytometry and reveal a strong increase of Tc17 cells in active disease, mainly due to induction of conventional T cells. Mass cytometry shows that Tc17 cells express a distinct immune signature (CD6 high , CD39, CD69, PD-1, CD27 low ) which was validated in an independent patient cohort. This signature stratifies patients into groups with distinct flare-free survival associated with differential CD6 expression. Targeting of CD6 in vitro reduces IL-17, IFN-γ and TNF production. These results identify a distinct Tc17 cell population in Crohn's disease with proinflammatory features linked to disease activity. The Tc17 signature informs clinical outcomes and may guide personalized treatment decisions.
Keyphrases
- induced apoptosis
- single cell
- cell cycle arrest
- end stage renal disease
- rheumatoid arthritis
- disease activity
- peripheral blood
- newly diagnosed
- ejection fraction
- chronic kidney disease
- systemic lupus erythematosus
- free survival
- immune response
- peritoneal dialysis
- oxidative stress
- prognostic factors
- poor prognosis
- stem cells
- signaling pathway
- pi k akt
- dna methylation
- drug delivery
- gene expression
- ankylosing spondylitis
- rheumatoid arthritis patients
- patient reported outcomes
- juvenile idiopathic arthritis
- cell therapy
- bone marrow